Cardiovascular complications in diabetes mellitus.

[1]  J. Gore,et al.  Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. , 2004, Archives of internal medicine.

[2]  M. Rutter,et al.  C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.

[3]  B. Sobel,et al.  Angiotensin-Converting Enzyme Inhibition Attenuates Hypofibrinolysis and Reduces Cardiac Perivascular Fibrosis in Genetically Obese Diabetic Mice , 2001, Circulation.

[4]  V. Thohan,et al.  Aldosterone antagonism and congestive heart failure: a new look at an old therapy , 2004, Current opinion in cardiology.

[5]  J. Ottervanger,et al.  Long-term, cause-specific mortality after myocardial infarction in diabetes. , 2004, European heart journal.

[6]  C. Torp‐Pedersen,et al.  Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. , 2004, Journal of the American College of Cardiology.

[7]  S. Neubauer,et al.  Reduced Vascular NO Bioavailability in Diabetes Increases Platelet Activation In Vivo , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[8]  G. Berglund,et al.  Tobacco and myocardial infarction in middle‐aged women: a study of factors modifying the risk , 2004, Journal of internal medicine.

[9]  K. Malmberg,et al.  Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. , 2004, Journal of the American College of Cardiology.

[10]  G. Lip,et al.  Soluble CD40 Ligand, Soluble P-Selectin, Interleukin-6, and Tissue Factor in Diabetes Mellitus: Relationships to Cardiovascular Disease and Risk Factor Intervention , 2004, Circulation.

[11]  C. Schalkwijk,et al.  More Fibrosis and Thrombotic Complications but Similar Expression Patterns of Markers for Coagulation and Inflammation in Symptomatic Plaques from DM2 Patients , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  M. Hirai,et al.  Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. , 2004, The American journal of pathology.

[13]  E. Rimm,et al.  C-reactive protein and incident cardiovascular events among men with diabetes. , 2004, Diabetes care.

[14]  R. de Caterina,et al.  Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. , 2004, Cardiovascular research.

[15]  M. Davies,et al.  Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. , 1993, British heart journal.

[16]  B. Sobel,et al.  Medical Management of Diabetes and Heart Disease , 2002 .

[17]  S. Reis,et al.  Clinical Importance of Obesity Versus the Metabolic Syndrome in Cardiovascular Risk in Women: A Report From the Women’s Ischemia Syndrome Evaluation (WISE) Study , 2004, Circulation.

[18]  Henrik Vestergaard,et al.  The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. , 2004, Archives of internal medicine.

[19]  Howard Cabral,et al.  Tight Glycemic Control in Diabetic Coronary Artery Bypass Graft Patients Improves Perioperative Outcomes and Decreases Recurrent Ischemic Events , 2004, Circulation.

[20]  B. Sobel,et al.  Attenuation of Neointimal Vascular Smooth Muscle Cellularity in Atheroma by Plasminogen Activator Inhibitor Type 1 (PAI-1) , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  R. Kronmal,et al.  The association of fasting glucose levels with congestive heart failure in diabetic adults > or =65 years: the Cardiovascular Health Study. , 2004, Journal of the American College of Cardiology.

[22]  Merlin C. Thomas,et al.  Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. , 2004, Diabetes.

[23]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[24]  M. Pfeffer,et al.  Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. , 2003, Journal of the American College of Cardiology.

[25]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[26]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[27]  Irene M Stratton,et al.  Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. , 2004, Diabetes care.

[28]  L. Bouter,et al.  Left ventricular mass increases with deteriorating glucose tolerance, especially in women: independence of increased arterial stiffness or decreased flow-mediated dilation: the Hoorn study. , 2004, Diabetes care.

[29]  V. Fuster,et al.  Angiographic progression of coronary artery disease and the development of myocardial infarction. , 1988, Journal of the American College of Cardiology.

[30]  W. Santamore,et al.  Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? , 1988, Circulation.

[31]  D. Yellon,et al.  Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. , 2003, Journal of the American College of Cardiology.

[32]  J. Izzo,et al.  Arterial stiffness and the systolic hypertension syndrome , 2004, Current opinion in cardiology.

[33]  E. Frohlich,et al.  Crosslink breakers: a new approach to cardiovascular therapy , 2004, Current opinion in cardiology.

[34]  K. Weber,et al.  Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. , 1995, European heart journal.

[35]  T. Elasy,et al.  Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: a consensus statement from the American Heart Association and American Diabetes Association Response to Nesto , 2004 .

[36]  P. Grant,et al.  Associations between insulin resistance and thrombotic risk factors in high‐risk South Asian subjects , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[37]  H. Himsworth.  DIABETES MELLITUS: ITS DIFFERENTIATION INTO INSULIN-SENSITIVE AND INSULIN-INSENSITIVE TYPES , 1936 .

[38]  S. Yusuf,et al.  Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.

[39]  R. Bergman,et al.  Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. , 2004, Diabetes care.

[40]  K. Malmberg.  Role of insulin-glucose infusion in outcomes after acute myocardial infarction: the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[41]  David L. Brown,et al.  Effect of diabetes on long-term mortality following contemporary percutaneous coronary intervention: analysis of 4,284 cases. , 2004, Diabetes care.

[42]  A. Takeshita,et al.  Pioglitazone, a Peroxisome Proliferator-Activated Receptor-&ggr; Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction , 2002, Circulation.

[43]  B. Sobel,et al.  Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. , 2003, The American journal of cardiology.

[44]  M. Hori,et al.  Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. , 2003, Journal of the American College of Cardiology.

[45]  G. Norton,et al.  Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. , 1996, Circulation.

[46]  L. Sleeper,et al.  Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. , 2004, Journal of the American College of Cardiology.

[47]  P. Mehler,et al.  Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients With Peripheral Arterial Disease and Type 2 Diabetes , 2003, Circulation.

[48]  B. Sobel,et al.  Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[49]  R. Virmani,et al.  Morphologic Findings of Coronary Atherosclerotic Plaques in Diabetics: A Postmortem Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[50]  O. Wagner,et al.  Joint Effects of C-Reactive Protein and Glycated Hemoglobin in Predicting Future Cardiovascular Events of Patients With Advanced Atherosclerosis , 2003, Circulation.

[51]  B. Sobel,et al.  Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. , 2004, The American journal of cardiology.